Search results
Order by most recent / most popular / relevance
Results: 1-10 of 11
Putative class alleges pharma statements about new drug violated securities laws
- Shook Hardy & Bacon LLP
- -
- USA
- -
- May 16 2013
Aveo Pharmaceuticals, Inc. and several of its executives have been targeted in a securities class action filed in a federal court in Massachusetts
Study shows R&D spending in biotech has rebounded
- Shook Hardy & Bacon LLP
- -
- USA
- -
- October 3 2012
Accounting and consulting group BDO USA has released a report based on information from publicly traded companies’ 10K U.S. Securities and Exchange Commission forms showing that research and development (R&D) spending in the biotechnology sector grew 5 percent in 2011, with biotech companies spending, on average, $50 million in 2011, an increase of $3 million invested in R&D in 2010
IPOs sluggish in 2011 on disappointing returns
- Shook Hardy & Bacon LLP
- -
- USA
- -
- January 19 2012
Biotech initial public offerings (IPOs) tracked the market as a whole in 2011, with fewer filed and returns in the negative column
PROLOR Biotech to raise $75 million for clinical trials on growth hormones
- Shook Hardy & Bacon LLP
- -
- Israel, USA
- -
- April 19 2012
In an April 6, 2012, filing with the U.S. Securities and Exchange Commission, Israel-based PROLOR Biotech, Inc. has registered the sale of common stock on the American Stock Exchange in an amount not to exceed $75 million
Eighth Circuit allows investor suit to proceed against pharmaceutical co
- Shook Hardy & Bacon LLP
- -
- USA
- -
- June 7 2012
The Eighth Circuit Court of Appeals has determined that investors alleging securities fraud against a pharmaceutical company which claimed in its Securities and Exchange Commission filings that it was in material compliance with Food and Drug Administration (FDA) regulations sufficiently pleaded that the claims were false or misleading
WSJ says venture capital tougher to find for biotech companies
- Shook Hardy & Bacon LLP
- -
- USA
- -
- March 29 2012
Noting that venture capitalists invested just $3.92 billion in biotech companies in 2011, down from the $6.17 billion watermark in 2007, and that shares in biotechs that went public last year averaged nearly 30 percent less than their anticipated midpoint offering price, a recent Wall Street Journal article warns biotechs, “The gravy days are over”
Aastrom biosciences announces financing deal to advance CVD treatments
- Shook Hardy & Bacon LLP
- -
- USA
- -
- March 29 2012
Aastrom Biosciences, an Ann Arbor, Michigan-based biotech startup, has announced a $40-million financing deal with large institutional investor Eastern Capital Limited
$9.2 million in equity reported to SEC by stem-cell treatment corp.
- Shook Hardy & Bacon LLP
- -
- USA
- -
- August 30 2012
In a regulatory filing with the U.S. Securities and Exchange Commission (SEC), Fate Therapeutics, Inc. has reported that it raised $9.2 million in equity
PolyMedix expects to raise $25 million for antibiotic development
- Shook Hardy & Bacon LLP
- -
- USA
- -
- March 21 2013
PolyMedix, Inc. stockholders have overwhelmingly approved a reverse stock split of the company's common stock at a ratio of up to fifty-for-one
Two Boston-area biotechs set to raise $146 million in IPOs
- Shook Hardy & Bacon LLP
- -
- USA
- -
- March 21 2013
According to a news source, Enanta Pharmaceuticals, Inc. and Tetraphase Pharmaceuticals, Inc. were poised to raise a combined total of $146 million
Current Search
- Author - Madeleine McDonough
- Author - John D. Garretson
- Author - Patrick Henderson
- Jurisdiction - USA
- Workarea - Capital Markets